flavin-mononucleotide and Liver-Diseases

The available drugs for the treatment of chronic liver affections (the adequate model is chronic hepatitis C) include agents of metabolic therapy, whose efficacy is not always enough, that required the search for original mitochondrial substrates on the basis of succinate. Such agents were composed as a pharmaceutical group named "Substrates of Energetic Metabolism" or "Substrate Antihypoxants". The review presents the description of the pharmacological effects of remaxole and cytoflavin, evident from lower levels of active metabolites of oxygen that increases the clinical efficacy of the therapy. Their role in the metabolic reactions in chronic liver affections is exclusive and rather actual.

Topics: Apoptosis; Chronic Disease; Drug Combinations; Flavin Mononucleotide; Glutathione Disulfide; Hepatitis C, Chronic; Humans; Inosine Diphosphate; Lipid Peroxidation; Liver Diseases; Niacinamide; Protective Agents; Succinates

Topics: Animals; Biometry; Cell Nucleus; Chemical and Drug Induced Liver Injury; Endoplasmic Reticulum; Female; Flavin Mononucleotide; Flavin-Adenine Dinucleotide; Golgi Apparatus; Histocytochemistry; Liver; Liver Diseases; Lysosomes; Membranes; Mice; Microscopy, Electron; Microsomes, Liver; Mitochondria, Liver; Mitochondrial Swelling; Riboflavin; Time Factors; Vitamin B Deficiency

Topics: Female; Flavin Mononucleotide; Flavin-Adenine Dinucleotide; Flavins; Humans; Kidney; Kidney Diseases; Liver; Liver Cirrhosis; Liver Diseases; Male; Nutrition Surveys; Proteins; Riboflavin; Vitamins